Privately held Dyno Therapeutics Inc. has added another notch to its adeno-associated virus (AAV) vectors development ...

Roche will use Dyno’s technology, through which Dyno applies AI and high-throughput in vivo data collection to engineering AAV capsids.

George Church-founded Dyno Therapeutics Inc. is adding to its list of pharma deals by signing a second research collaboration ...

Our heart muscle is studded with tiny dyads, intricately designed structures that manage incoming electrical signals and ...

US artificial intelligence (AI) to gene therapy focussed biotech Dyno Therapeutics today announced its second research ...

Pharma presented positive preliminary data from eleven participants dosed in the CANaspire Phase 1/2 clinical trial of ...

The combined company, which will be called Opus Genetics, will focus on advancing a pipeline of gene therapies for inherited retinal diseases.

After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. | In a new deal potentially ...

With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy ...

Delve into the field of severe epilepsies as new treatments for Dravet syndrome are progressing through the pipeline.

Existing gene therapies have primarily used a small number of naturally occurring AAV vectors limited by low delivery efficiency as well as problems with pre-existing immunity and manufacturability.

Ocuphire Pharma acquires Opus Genetics, expanding its IRD gene therapy pipeline. The renamed company, Opus Genetics, will trade under "IRD" by late024.